gp100 (209-217), G209-2M - 1 mg
- Cat.Number : AS-61277
- Manufacturer Ref. :
-
Availability :
In stock
This modified gp100 peptide amino acids 209 to 217 is a MHC-associated HLA-A2.1-restricted epitope derived from melanoma antigene. It can be processed, presented, and recognized by T cells. Alteration of the G209 peptide to G209-2M at the second amino acid changing threonine to a methionine was found to increase the affinity for MHC-associated HLA-A2.1 resulting in enhanced induction of T cells reactive to native gp100.
Specifications
Chemistry | |
Sequence one letter code |
|
---|---|
Sequence three letter code |
|
Molecular Formula |
|
Molecular Mass/ Weight |
|
Modification | |
Conjugation |
|
Quantity & Purity | |
Purity |
|
Storage & stability | |
Form |
|
Storage Conditions |
|
Activity | |
Biomarker Target | |
Research Area | |
Sub-category Research Area | |
Usage |
|
Source | |
Source / Species |
|
Downloads
You may also be interested in the following product(s)

SensoLyte® Rh110 Matriptase Activity Assay Kit Fluorimetric - 1 kit

References
Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells
JEM . 2004 Jun 01 ; 199(11) 1503 | DOI : https://doi.org/10.1084/jem.20032118
- S. Paczesny
- et al
T-cell responses against tyrosinase 368-376(370D) peptide in HLA A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants
Clin. Canc. Res. . 2002 May 01 ; 8(5) 967 | DOI : PMID: 12006508
- S. Schaed
- et al